Pharmaceuticals, Biotechnology and Life Sciences
First patient dosed in the global, pivotal, Phase 3 RAISE study of zilucoplan in gMG, with top-line results expected in…
CHICAGO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid…
Dosing of first Fabry patient incorporating plato™ anticipated for fourth quarter 2019 All Fabry patients who discontinued enzyme replacement therapy…
–Conference Call and Webcast Today at 8:00 a.m. ET– WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused…
Part I of Adaptive RENEW Phase 3 Clinical Trial in Dry Eye Disease on Track for Completion in Fourth Quarter…
– BT7480 selected as lead immuno-oncology candidate to advance into IND-enabling studies – Preclinical data on Bicycle® tumor-targeted immune cell…
CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases…
Remission maintenance and structural damage inhibition findings from the Phase IIIb AVERT-2 study highlight potential role for ORENCIA in de-escalation…
NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers Squibb”) announced today the extension of the expiration date of the offers to…
DUBLIN–(BUSINESS WIRE)–The “Anti-Hypertensive Drugs Global Market Report 2020” report has been added to ResearchAndMarkets.com’s offering. Where is the largest and…